The number of people with susceptibility test result for rifampicin in Kyrgyzstan
Kyrgyzstan: The number of people with susceptibility test result for rifampicin was 94.01 in 2021. ▲ Rising
Latest (2021)
94.01
Change on year
up 2.2%
World rank
56th
of 146 countries
All-time high
94.01
in 2021
All-time low
86.7
in 2017
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Kyrgyzstan, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
In 2021, the number of people with susceptibility test result for rifampicin in Kyrgyzstan stood at 94.01. That is the highest value across all 5 years on record.
That represents a change of up 2.2% on the previous year and up 8.4% over five years.
Kyrgyzstan ranks 56th of 146 countries on this measure, in the middle of the range.
The number of people with susceptibility test result for rifampicin in Kyrgyzstan, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 86.7 | — |
| 2018 | 89.84 | +3.6% |
| 2019 | 93.17 | +3.7% |
| 2020 | 92.02 | -1.2% |
| 2021 | 94.01 | +2.2% |
Kyrgyzstan compared with similar countries
- Kyrgyzstan's 94.01 is above the median for lower middle income countries, which is 78.77, 1.2× the median. (32 countries reporting)
- Kyrgyzstan's 94.01 is above the median for Europe & Central Asia, which is 93.52, 1.0× the median. (43 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 89.91 | 86.7 | 93.17 | 3 |
| 2020s | 93.02 | 92.02 | 94.01 | 2 |
Countries ranked near Kyrgyzstan
More health data for Kyrgyzstan
- Un projection of annual infant deaths, annual growth rate -1.77 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6971 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 938.9 deaths per 1,000 people (2090)
- Number of infants who die before age 1 278 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2023)
- Population ages 00-04, female, annual growth rate -1.95 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0501 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.01 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Kyrgyzstan?
- The number of people with susceptibility test result for rifampicin in Kyrgyzstan was 94.01 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Kyrgyzstan?
- The highest recorded value was 94.01 in 2021.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Kyrgyzstan?
- The lowest recorded value was 86.7 in 2017.
- How does Kyrgyzstan rank for the number of people with susceptibility test result for rifampicin?
- Kyrgyzstan ranks 56th out of 146 countries with data for 2021.
- Where does this Kyrgyzstan data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).